Lancet子刊:纪立农教授对糖尿病重新进行分型

2018-12-30 MedSci MedSci原创

一说糖尿病,很多人会想到1型糖尿病和2型糖尿病,但当前是个讲究精准治疗的时代,两种分型似乎显得粗糙些。 近日,北大人民医院纪立农团队对此进行了探究并重新分为4个亚型:严重胰岛素缺乏糖尿病(SIDD)、严重胰岛素抵抗糖尿病(SIRD)、中度肥胖相关糖尿病(MOD)和中度年龄相关糖尿病(MARD)。 图1 中美新诊糖尿病人群各亚型的临床特征 这一研究中,研究者就

一说糖尿病,很多人会想到1型糖尿病和2型糖尿病,但当前是个讲究精准治疗的时代,两种分型似乎显得粗糙些。

近日,北大人民医院纪立农团队对此进行了探究并重新分为4个亚型:严重胰岛素缺乏糖尿病(SIDD)、严重胰岛素抵抗糖尿病(SIRD)、中度肥胖相关糖尿病(MOD)和中度年龄相关糖尿病(MARD)。

 


图1 中美新诊糖尿病人群各亚型的临床特征

这一研究中,研究者就中美流行病学调查的新诊断糖尿病人群,通过人工智能中的聚类方法,以年龄、体重指数、血糖水平、胰岛素敏感性指数及胰岛细胞功能指数等5个维度进行了分型。

各亚型的主要临床特征在中美人群以及不同种族的人群中基本一致,并与原北欧人群的亚型特点相重合。

采用人工智能的tSNE可视化方法对样本进行三维投射,各亚群之间从图像上彼此独立,相应视频在LancetTV同期发表。

该研究迈出了中国人群的糖尿病精准分型及治疗的第一步。

原始出处:

Zou X,Zhou X, Zhu Z, et al. Novel subgroups of patients with adult-onset diabetes in Chinese and US populations. Lancet Diabetes Endocrinol, 2019, 7(1):9-11.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1829917, encodeId=8bc4182991e2f, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Mar 09 23:07:00 CST 2019, time=2019-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077977, encodeId=e1e120e7977f8, content=<a href='/topic/show?id=3958e731687' target=_blank style='color:#2F92EE;'>#纪立农#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77316, encryptionId=3958e731687, topicName=纪立农)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cdcd18, createdName=bshuang, createdTime=Sun Jun 16 07:07:00 CST 2019, time=2019-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=357003, encodeId=076335e00339, content=有意义吗,研究点治愈重点行吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae582369854, createdName=122eea35m99暂无昵称, createdTime=Wed Jan 02 20:28:14 CST 2019, time=2019-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356987, encodeId=b12e35698e73, content=对于不同亚型不同防治策略,好文,值得学习~, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2019/01/02/06ff336a9fc3d156e1a30ee3d3448a83.jpg, createdBy=31f41577443, createdName=417735661, createdTime=Wed Jan 02 13:37:32 CST 2019, time=2019-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356812, encodeId=9c6e3568124c, content=学习学习谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Mon Dec 31 09:07:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356774, encodeId=decc356e74f4, content=好文,值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ef781002, createdName=topnew, createdTime=Sun Dec 30 20:03:25 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356772, encodeId=0d94356e727a, content=认真学习,不断进步,把经验分享给同好。点赞了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=d85d1636106, createdName=lietome2, createdTime=Sun Dec 30 19:24:53 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042177, encodeId=3b4f10421e7bf, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Dec 30 19:07:00 CST 2018, time=2018-12-30, status=1, ipAttribution=)]
    2019-03-09 howi
  2. [GetPortalCommentsPageByObjectIdResponse(id=1829917, encodeId=8bc4182991e2f, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Mar 09 23:07:00 CST 2019, time=2019-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077977, encodeId=e1e120e7977f8, content=<a href='/topic/show?id=3958e731687' target=_blank style='color:#2F92EE;'>#纪立农#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77316, encryptionId=3958e731687, topicName=纪立农)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cdcd18, createdName=bshuang, createdTime=Sun Jun 16 07:07:00 CST 2019, time=2019-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=357003, encodeId=076335e00339, content=有意义吗,研究点治愈重点行吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae582369854, createdName=122eea35m99暂无昵称, createdTime=Wed Jan 02 20:28:14 CST 2019, time=2019-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356987, encodeId=b12e35698e73, content=对于不同亚型不同防治策略,好文,值得学习~, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2019/01/02/06ff336a9fc3d156e1a30ee3d3448a83.jpg, createdBy=31f41577443, createdName=417735661, createdTime=Wed Jan 02 13:37:32 CST 2019, time=2019-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356812, encodeId=9c6e3568124c, content=学习学习谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Mon Dec 31 09:07:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356774, encodeId=decc356e74f4, content=好文,值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ef781002, createdName=topnew, createdTime=Sun Dec 30 20:03:25 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356772, encodeId=0d94356e727a, content=认真学习,不断进步,把经验分享给同好。点赞了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=d85d1636106, createdName=lietome2, createdTime=Sun Dec 30 19:24:53 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042177, encodeId=3b4f10421e7bf, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Dec 30 19:07:00 CST 2018, time=2018-12-30, status=1, ipAttribution=)]
    2019-06-16 bshuang
  3. [GetPortalCommentsPageByObjectIdResponse(id=1829917, encodeId=8bc4182991e2f, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Mar 09 23:07:00 CST 2019, time=2019-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077977, encodeId=e1e120e7977f8, content=<a href='/topic/show?id=3958e731687' target=_blank style='color:#2F92EE;'>#纪立农#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77316, encryptionId=3958e731687, topicName=纪立农)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cdcd18, createdName=bshuang, createdTime=Sun Jun 16 07:07:00 CST 2019, time=2019-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=357003, encodeId=076335e00339, content=有意义吗,研究点治愈重点行吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae582369854, createdName=122eea35m99暂无昵称, createdTime=Wed Jan 02 20:28:14 CST 2019, time=2019-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356987, encodeId=b12e35698e73, content=对于不同亚型不同防治策略,好文,值得学习~, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2019/01/02/06ff336a9fc3d156e1a30ee3d3448a83.jpg, createdBy=31f41577443, createdName=417735661, createdTime=Wed Jan 02 13:37:32 CST 2019, time=2019-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356812, encodeId=9c6e3568124c, content=学习学习谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Mon Dec 31 09:07:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356774, encodeId=decc356e74f4, content=好文,值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ef781002, createdName=topnew, createdTime=Sun Dec 30 20:03:25 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356772, encodeId=0d94356e727a, content=认真学习,不断进步,把经验分享给同好。点赞了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=d85d1636106, createdName=lietome2, createdTime=Sun Dec 30 19:24:53 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042177, encodeId=3b4f10421e7bf, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Dec 30 19:07:00 CST 2018, time=2018-12-30, status=1, ipAttribution=)]
    2019-01-02 122eea35m99暂无昵称

    有意义吗,研究点治愈重点行吗

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1829917, encodeId=8bc4182991e2f, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Mar 09 23:07:00 CST 2019, time=2019-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077977, encodeId=e1e120e7977f8, content=<a href='/topic/show?id=3958e731687' target=_blank style='color:#2F92EE;'>#纪立农#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77316, encryptionId=3958e731687, topicName=纪立农)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cdcd18, createdName=bshuang, createdTime=Sun Jun 16 07:07:00 CST 2019, time=2019-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=357003, encodeId=076335e00339, content=有意义吗,研究点治愈重点行吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae582369854, createdName=122eea35m99暂无昵称, createdTime=Wed Jan 02 20:28:14 CST 2019, time=2019-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356987, encodeId=b12e35698e73, content=对于不同亚型不同防治策略,好文,值得学习~, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2019/01/02/06ff336a9fc3d156e1a30ee3d3448a83.jpg, createdBy=31f41577443, createdName=417735661, createdTime=Wed Jan 02 13:37:32 CST 2019, time=2019-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356812, encodeId=9c6e3568124c, content=学习学习谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Mon Dec 31 09:07:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356774, encodeId=decc356e74f4, content=好文,值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ef781002, createdName=topnew, createdTime=Sun Dec 30 20:03:25 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356772, encodeId=0d94356e727a, content=认真学习,不断进步,把经验分享给同好。点赞了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=d85d1636106, createdName=lietome2, createdTime=Sun Dec 30 19:24:53 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042177, encodeId=3b4f10421e7bf, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Dec 30 19:07:00 CST 2018, time=2018-12-30, status=1, ipAttribution=)]
    2019-01-02 417735661

    对于不同亚型不同防治策略,好文,值得学习~

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1829917, encodeId=8bc4182991e2f, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Mar 09 23:07:00 CST 2019, time=2019-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077977, encodeId=e1e120e7977f8, content=<a href='/topic/show?id=3958e731687' target=_blank style='color:#2F92EE;'>#纪立农#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77316, encryptionId=3958e731687, topicName=纪立农)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cdcd18, createdName=bshuang, createdTime=Sun Jun 16 07:07:00 CST 2019, time=2019-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=357003, encodeId=076335e00339, content=有意义吗,研究点治愈重点行吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae582369854, createdName=122eea35m99暂无昵称, createdTime=Wed Jan 02 20:28:14 CST 2019, time=2019-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356987, encodeId=b12e35698e73, content=对于不同亚型不同防治策略,好文,值得学习~, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2019/01/02/06ff336a9fc3d156e1a30ee3d3448a83.jpg, createdBy=31f41577443, createdName=417735661, createdTime=Wed Jan 02 13:37:32 CST 2019, time=2019-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356812, encodeId=9c6e3568124c, content=学习学习谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Mon Dec 31 09:07:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356774, encodeId=decc356e74f4, content=好文,值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ef781002, createdName=topnew, createdTime=Sun Dec 30 20:03:25 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356772, encodeId=0d94356e727a, content=认真学习,不断进步,把经验分享给同好。点赞了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=d85d1636106, createdName=lietome2, createdTime=Sun Dec 30 19:24:53 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042177, encodeId=3b4f10421e7bf, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Dec 30 19:07:00 CST 2018, time=2018-12-30, status=1, ipAttribution=)]
    2018-12-31 kafei

    学习学习谢谢

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1829917, encodeId=8bc4182991e2f, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Mar 09 23:07:00 CST 2019, time=2019-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077977, encodeId=e1e120e7977f8, content=<a href='/topic/show?id=3958e731687' target=_blank style='color:#2F92EE;'>#纪立农#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77316, encryptionId=3958e731687, topicName=纪立农)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cdcd18, createdName=bshuang, createdTime=Sun Jun 16 07:07:00 CST 2019, time=2019-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=357003, encodeId=076335e00339, content=有意义吗,研究点治愈重点行吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae582369854, createdName=122eea35m99暂无昵称, createdTime=Wed Jan 02 20:28:14 CST 2019, time=2019-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356987, encodeId=b12e35698e73, content=对于不同亚型不同防治策略,好文,值得学习~, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2019/01/02/06ff336a9fc3d156e1a30ee3d3448a83.jpg, createdBy=31f41577443, createdName=417735661, createdTime=Wed Jan 02 13:37:32 CST 2019, time=2019-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356812, encodeId=9c6e3568124c, content=学习学习谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Mon Dec 31 09:07:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356774, encodeId=decc356e74f4, content=好文,值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ef781002, createdName=topnew, createdTime=Sun Dec 30 20:03:25 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356772, encodeId=0d94356e727a, content=认真学习,不断进步,把经验分享给同好。点赞了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=d85d1636106, createdName=lietome2, createdTime=Sun Dec 30 19:24:53 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042177, encodeId=3b4f10421e7bf, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Dec 30 19:07:00 CST 2018, time=2018-12-30, status=1, ipAttribution=)]
    2018-12-30 topnew

    好文,值得推荐

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1829917, encodeId=8bc4182991e2f, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Mar 09 23:07:00 CST 2019, time=2019-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077977, encodeId=e1e120e7977f8, content=<a href='/topic/show?id=3958e731687' target=_blank style='color:#2F92EE;'>#纪立农#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77316, encryptionId=3958e731687, topicName=纪立农)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cdcd18, createdName=bshuang, createdTime=Sun Jun 16 07:07:00 CST 2019, time=2019-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=357003, encodeId=076335e00339, content=有意义吗,研究点治愈重点行吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae582369854, createdName=122eea35m99暂无昵称, createdTime=Wed Jan 02 20:28:14 CST 2019, time=2019-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356987, encodeId=b12e35698e73, content=对于不同亚型不同防治策略,好文,值得学习~, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2019/01/02/06ff336a9fc3d156e1a30ee3d3448a83.jpg, createdBy=31f41577443, createdName=417735661, createdTime=Wed Jan 02 13:37:32 CST 2019, time=2019-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356812, encodeId=9c6e3568124c, content=学习学习谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Mon Dec 31 09:07:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356774, encodeId=decc356e74f4, content=好文,值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ef781002, createdName=topnew, createdTime=Sun Dec 30 20:03:25 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356772, encodeId=0d94356e727a, content=认真学习,不断进步,把经验分享给同好。点赞了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=d85d1636106, createdName=lietome2, createdTime=Sun Dec 30 19:24:53 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042177, encodeId=3b4f10421e7bf, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Dec 30 19:07:00 CST 2018, time=2018-12-30, status=1, ipAttribution=)]
    2018-12-30 lietome2

    认真学习,不断进步,把经验分享给同好。点赞了!

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1829917, encodeId=8bc4182991e2f, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Mar 09 23:07:00 CST 2019, time=2019-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077977, encodeId=e1e120e7977f8, content=<a href='/topic/show?id=3958e731687' target=_blank style='color:#2F92EE;'>#纪立农#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77316, encryptionId=3958e731687, topicName=纪立农)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cdcd18, createdName=bshuang, createdTime=Sun Jun 16 07:07:00 CST 2019, time=2019-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=357003, encodeId=076335e00339, content=有意义吗,研究点治愈重点行吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae582369854, createdName=122eea35m99暂无昵称, createdTime=Wed Jan 02 20:28:14 CST 2019, time=2019-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356987, encodeId=b12e35698e73, content=对于不同亚型不同防治策略,好文,值得学习~, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2019/01/02/06ff336a9fc3d156e1a30ee3d3448a83.jpg, createdBy=31f41577443, createdName=417735661, createdTime=Wed Jan 02 13:37:32 CST 2019, time=2019-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356812, encodeId=9c6e3568124c, content=学习学习谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Mon Dec 31 09:07:00 CST 2018, time=2018-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356774, encodeId=decc356e74f4, content=好文,值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ef781002, createdName=topnew, createdTime=Sun Dec 30 20:03:25 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356772, encodeId=0d94356e727a, content=认真学习,不断进步,把经验分享给同好。点赞了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRuUXgacXpPeW0x8Z3Qr9c3I2kTic4ZIpR29iaftYgkjRcbv982icYMtqANBPYBgPnOia6mVtX76qMXuc/0, createdBy=d85d1636106, createdName=lietome2, createdTime=Sun Dec 30 19:24:53 CST 2018, time=2018-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042177, encodeId=3b4f10421e7bf, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Dec 30 19:07:00 CST 2018, time=2018-12-30, status=1, ipAttribution=)]
    2018-12-30 misszhang

    谢谢MedSci提供最新的资讯

    0

相关资讯

CSE 2014:纪立农教授解读二甲双胍临床应用专家共识

为指导临床医生和患者正确认识并合理使用二甲双胍,多位内分泌临床专家、药学专家共同参与制订了《二甲双胍临床应用专家共识》。8月28日下午在第十三次全国内分泌学学术会议(CSE2014)的“ 糖尿病年度进展及治疗新方法”专题发言上,北京大学人民医院纪立农教授代表共识专家组对《二甲双胍临床应用专家共识》作了精彩解读! 一、无论对于超重、肥胖的患者还是体重正常的患者,除非存在禁忌证或不耐受,否则

纪立农教授再谈糖尿病肾病的预测因素

导语:2016年9月,北京大学人民医院内分泌科纪立农教授团队在Diabetes Technology & Therapeutics杂志发表了一项回顾性队列研究。通过收集分析住院2型糖尿病(T2DM)患者数据,探讨T2DM患者(包括正常白蛋白尿者)肾功能下降的主要危险因素。临床上普遍认为白蛋白尿是糖尿病肾病的重要标志物之一,但近年来,越来越多的证据表明,对于某些T2DM患者而言,肾功能改变与

纪立农当选国际糖尿病联盟西太平洋区候任主席

北京大学人民医院纪立农教授当选国际糖尿病联盟西太平洋区候任主席 2015年11月29日,在国际糖尿病联盟西太平洋区(IDF-WPR)理事会上,北京大学人民医院内分泌科主任纪立农教授高票当选为新一届IDF-WPR候任主席。这是中国大陆专家首次担任该重量级国际糖尿病组织要职。纪立农教授的当选标志着中国糖尿病界在国际糖尿病领域的地位有了突破性的提高,将进一步推动中国糖尿病事业的发展。 糖尿病在全球范

CDS 2015:纪立农教授公布SGLT-2抑制剂心血管终点(Empa-REG OT 研究)

在探讨新型降糖药钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂恩格列(empagliflozin)对心血管事件和死亡率的影响。研究纳入7020 例2型糖尿病(T2DM)心血管事件高危患者,在标准治疗基础上1︰1︰1 随机给予恩格列净10 mg、恩格列净25 mg或安慰剂,平均随访3.1年。主要终点为心血管死亡、非致死性心梗和非致死性卒中组成的复合终点。主要的次要复合终点为主要终点+不稳定心绞痛住院。

CDS 2016:纪立农教授荣获2016年度科学贡献奖,附获奖演讲

由中华医学会、中华医学会糖尿病学分会主办,厦门市医学会承办的中华医学会糖尿病学分会第二十次全国学术会议于2016年11月17在美丽的鹭岛厦门盛大召开。18日下午,CDS的科学贡献奖颁奖仪式及获奖报告在C3展厅隆重举行,本次的获奖者为北京大学人民医院的纪立农教授。科学贡献奖是 CDS 的最高学术奖项,旨在对国内从事糖尿病研究的杰出科研工作者进行表彰,从而鼓励和引导更多同道投身糖尿病科研,促进我国糖尿

2016 CDS:梅斯医学专访纪立农教授:我们需要“中国原创”的临床证据

2016年11月16日~19日,由中华医学会、中华医学会糖尿病学分会(CDS)主办,厦门市医学会承办的中华医学会糖尿病学分会第二十次全国学术会议(CDS 2016)在福建厦门召开。中华医学会糖尿病分会(CDS)自2014年开始设立科学贡献奖,是CDS的最高学术奖项,旨在对国内从事糖尿病研究的杰出科研工作者进行表彰,从而鼓励和引导更多同道投身糖尿病科研,促进我国糖尿病防治工作的进步。今年科学贡献奖颁